Strategies for the Next Generation of Antibody-Drug Conjugates: Utilizing Tumor Immunology and Microenvironmental Factors in ADC Design
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: 20 November 2024 | Viewed by 108
Special Issue Editor
2. Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
Interests: bioconjugation; ADC; peptide chemistry; chemical biology; automated synthesis
Special Issue Information
Dear Colleagues,
We are pleased to invite you to submit a paper to a Special Issue of Pharmaceutics entitled “Strategies for the Next Generation of Antibody–Drug Conjugates: Utilizing Tumor Immunology and Microenvironmental Factors in ADC Design”.
Over the past decade, we witnessed the extraordinary success story of ADCs. This new therapeutic modality has been proven to target tumor cells with unparalleled precision and efficacy.
To date, traditional ADC designs have reached their limitations: (i) the majority of targetable cancer antigens are identified and well characterized; (ii) linker technologies, once the major drawback of effective ADC construction, are fully optimized; and (iii) various payloads that represent a broad variety of anti-cancer mechanisms of action are readily available. Although the first chapter of the ADC story is now behind us, the existing technological know-how and the clinical experience warrant the development of the next generation of ADCs. These new chemo-biological entities should be able to tackle the challenges of tumor heterogeneity and drug resistance.
This Special Issue aims to deliver a full inventory of the various formats of novel ADC designs, and explore their interaction with the tumor microenvironment (e.g., probody–drug conjugates), as well as their potential to improve their therapeutic efficacy via immune-stimulating modifications (e.g., ISACs).
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: design, synthesis and evaluation of ADCs, with a special focus on their linkers and payloads as responsive elements for the tumor microenvironment, and immune stimulation design approaches. Due to the increasing diversity of ADC formats, articles encompassing a comparative analysis of traditional and developmental platforms are highly welcome.
I look forward to receiving your contribution.
Dr. Zoltan Szekely
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody–drug conjugate
- bio-conjugation
- bispecific ADCs
- linker design
- cytotoxic payloads
- dual-drug ADCs
- probody–drug conjugates
- tumor immunology
- tumor microenvironment
